Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Lactoferrin-induced myeloid-derived suppressor cell therapy attenuates pathologic inflammatory conditions in newborn mice.

Liu Y, Perego M, Xiao Q, He Y, Fu S, He J, Liu W, Li X, Tang Y, Li X, Yuan W, Zhou W, Wu F, Jia C, Cui Q, Worthen GS, Jensen EA, Gabrilovich DI, Zhou J.

J Clin Invest. 2019 Sep 4. pii: 128164. doi: 10.1172/JCI128164. [Epub ahead of print]

2.

HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.

Fukumoto T, Fatkhutdinov N, Zundell JA, Tcyganov EN, Nacarelli T, Karakashev S, Wu S, Liu Q, Gabrilovich DI, Zhang R.

Cancer Res. 2019 Jul 16. pii: canres.1302.2019. doi: 10.1158/0008-5472.CAN-19-1302. [Epub ahead of print]

PMID:
31311810
3.

Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs.

Mastio J, Condamine T, Dominguez G, Kossenkov AV, Donthireddy L, Veglia F, Lin C, Wang F, Fu S, Zhou J, Viatour P, Lavilla-Alonso S, Polo AT, Tcyganov EN, Mulligan C Jr, Nam B, Bennett J, Masters G, Guarino M, Kumar A, Nefedova Y, Vonderheide RH, Languino LR, Abrams SI, Gabrilovich DI.

J Exp Med. 2019 Sep 2;216(9):2150-2169. doi: 10.1084/jem.20181952. Epub 2019 Jun 25.

PMID:
31239386
4.

Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth.

Agarwal E, Altman BJ, Seo JH, Ghosh JC, Kossenkov AV, Tang HY, Krishn SR, Languino LR, Gabrilovich DI, Speicher DW, Dang CV, Altieri DC.

J Biol Chem. 2019 Jul 5;294(27):10407-10414. doi: 10.1074/jbc.AC119.008656. Epub 2019 May 16.

5.

Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis.

Agarwal E, Altman BJ, Ho Seo J, Bertolini I, Ghosh JC, Kaur A, Kossenkov AV, Languino LR, Gabrilovich DI, Speicher DW, Dang CV, Altieri DC.

Mol Cell Biol. 2019 Jun 27;39(14). pii: e00109-19. doi: 10.1128/MCB.00109-19. Print 2019 Jul 15.

PMID:
31061095
6.

Fatty acid transport protein 2 reprograms neutrophils in cancer.

Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, To TKJ, Schug Z, Basu S, Wang F, Ricciotti E, DiRusso C, Murphy ME, Vonderheide RH, Lieberman PM, Mulligan C, Nam B, Hockstein N, Masters G, Guarino M, Lin C, Nefedova Y, Black P, Kagan VE, Gabrilovich DI.

Nature. 2019 May;569(7754):73-78. doi: 10.1038/s41586-019-1118-2. Epub 2019 Apr 17.

PMID:
30996346
7.

"Redox lipidomics technology: Looking for a needle in a haystack".

Tyurina YY, Tyurin VA, Anthonymuthu T, Amoscato AA, Sparvero LJ, Nesterova AM, Baynard ML, Sun W, He R, Khaitovich P, Vladimirov YA, Gabrilovich DI, Bayır H, Kagan VE.

Chem Phys Lipids. 2019 Jul;221:93-107. doi: 10.1016/j.chemphyslip.2019.03.012. Epub 2019 Mar 27. Review.

8.

Transcriptional factor ATF3 protects against colitis by regulating follicular helper T cells in Peyer's patches.

Cao Y, Yang Q, Deng H, Tang J, Hu J, Liu H, Zhi M, Ye L, Zou B, Liu Y, Wei L, Gabrilovich DI, Wang H, Zhou J.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6286-6291. doi: 10.1073/pnas.1818164116. Epub 2019 Mar 12.

9.

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.

Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI.

Clin Cancer Res. 2019 May 1;25(9):2783-2794. doi: 10.1158/1078-0432.CCR-18-2725. Epub 2019 Feb 14.

PMID:
30765391
10.

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ.

Cancer Immunol Immunother. 2019 Mar;68(3):517-527. doi: 10.1007/s00262-018-2287-9. Epub 2018 Dec 27.

11.

The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer.

Kim HR, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, Cho BC, Seong SY, Ha SJ, Youn JI.

Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246. doi: 10.1164/rccm.201808-1502LE. No abstract available.

PMID:
30339766
12.

Unique pattern of neutrophil migration and function during tumor progression.

Patel S, Fu S, Mastio J, Dominguez GA, Purohit A, Kossenkov A, Lin C, Alicea-Torres K, Sehgal M, Nefedova Y, Zhou J, Languino LR, Clendenin C, Vonderheide RH, Mulligan C, Nam B, Hockstein N, Masters G, Guarino M, Schug ZT, Altieri DC, Gabrilovich DI.

Nat Immunol. 2018 Nov;19(11):1236-1247. doi: 10.1038/s41590-018-0229-5. Epub 2018 Oct 15.

13.

Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice.

Hashimoto A, Gao C, Mastio J, Kossenkov A, Abrams SI, Purandare AV, Desilva H, Wee S, Hunt J, Jure-Kunkel M, Gabrilovich DI.

Cancer Res. 2018 Oct 1;78(19):5644-5655. doi: 10.1158/0008-5472.CAN-18-1229. Epub 2018 Aug 23.

PMID:
30139814
14.

ICAM-1 controls development and function of ILC2.

Lei AH, Xiao Q, Liu GY, Shi K, Yang Q, Li X, Liu YF, Wang HK, Cai WP, Guan YJ, Gabrilovich DI, Zhou J.

J Exp Med. 2018 Aug 6;215(8):2157-2174. doi: 10.1084/jem.20172359. Epub 2018 Jul 26.

15.

ICAM-1 Deficiency in the Bone Marrow Niche Impairs Quiescence and Repopulation of Hematopoietic Stem Cells.

Liu YF, Zhang SY, Chen YY, Shi K, Zou B, Liu J, Yang Q, Jiang H, Wei L, Li CZ, Zhao M, Gabrilovich DI, Zhang H, Zhou J.

Stem Cell Reports. 2018 Jul 10;11(1):258-273. doi: 10.1016/j.stemcr.2018.05.016. Epub 2018 Jun 21.

16.

Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements.

Seo JH, Agarwal E, Bryant KG, Caino MC, Kim ET, Kossenkov AV, Tang HY, Languino LR, Gabrilovich DI, Cohen AR, Speicher DW, Altieri DC.

Cancer Res. 2018 Aug 1;78(15):4215-4228. doi: 10.1158/0008-5472.CAN-18-0595. Epub 2018 Jun 13.

17.

Understanding the tumor immune microenvironment (TIME) for effective therapy.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF.

Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23. Review.

18.

Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.

Tang CH, Chang S, Hashimoto A, Chen YJ, Kang CW, Mato AR, Del Valle JR, Gabrilovich DI, Hu CC.

Cancer Immunol Res. 2018 Jun;6(6):696-710. doi: 10.1158/2326-6066.CIR-17-0582. Epub 2018 Apr 12.

19.

CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients.

Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sasser K, Lee JW, Beatty GL, Gabrilovich DI, Rustgi AK.

JCI Insight. 2018 Mar 22;3(6). pii: 97022. doi: 10.1172/jci.insight.97022.

20.

Plasticity of myeloid-derived suppressor cells in cancer.

Tcyganov E, Mastio J, Chen E, Gabrilovich DI.

Curr Opin Immunol. 2018 Apr;51:76-82. doi: 10.1016/j.coi.2018.03.009. Epub 2018 Mar 14. Review.

21.

Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.

Lu H, Bowler N, Harshyne LA, Craig Hooper D, Krishn SR, Kurtoglu S, Fedele C, Liu Q, Tang HY, Kossenkov AV, Kelly WK, Wang K, Kean RB, Weinreb PH, Yu L, Dutta A, Fortina P, Ertel A, Stanczak M, Forsberg F, Gabrilovich DI, Speicher DW, Altieri DC, Languino LR.

Matrix Biol. 2018 Sep;70:20-35. doi: 10.1016/j.matbio.2018.03.009. Epub 2018 Mar 9.

22.

Phosphorylation of IRE1 at S729 regulates RIDD in B cells and antibody production after immunization.

Tang CH, Chang S, Paton AW, Paton JC, Gabrilovich DI, Ploegh HL, Del Valle JR, Hu CC.

J Cell Biol. 2018 May 7;217(5):1739-1755. doi: 10.1083/jcb.201709137. Epub 2018 Mar 6.

23.

Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation.

He YM, Li X, Perego M, Nefedova Y, Kossenkov AV, Jensen EA, Kagan V, Liu YF, Fu SY, Ye QJ, Zhou YH, Wei L, Gabrilovich DI, Zhou J.

Nat Med. 2018 Feb;24(2):224-231. doi: 10.1038/nm.4467. Epub 2018 Jan 15.

24.

Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer.

Veglia F, Tyurin VA, Mohammadyani D, Blasi M, Duperret EK, Donthireddy L, Hashimoto A, Kapralov A, Amoscato A, Angelini R, Patel S, Alicea-Torres K, Weiner D, Murphy ME, Klein-Seetharaman J, Celis E, Kagan VE, Gabrilovich DI.

Nat Commun. 2017 Dec 14;8(1):2122. doi: 10.1038/s41467-017-02186-9.

25.

A Bayesian pick-the-winner design in a randomized phase II clinical trial.

Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE.

Oncotarget. 2017 Jul 7;8(51):88376-88385. doi: 10.18632/oncotarget.19088. eCollection 2017 Oct 24.

26.

Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.

Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, Speicher DW, Weeraratna AT, Chao T, Vonderheide RH, Languino LR, Ordentlich P, Liu Q, Xu X, Lo A, Puré E, Zhang C, Loboda A, Sepulveda MA, Snyder LA, Gabrilovich DI.

Cancer Cell. 2017 Nov 13;32(5):654-668.e5. doi: 10.1016/j.ccell.2017.10.005.

27.

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ.

Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017.

28.

Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer.

Caino MC, Seo JH, Wang Y, Rivadeneira DB, Gabrilovich DI, Kim ET, Weeraratna AT, Languino LR, Altieri DC.

J Clin Invest. 2017 Oct 2;127(10):3755-3769. doi: 10.1172/JCI93172. Epub 2017 Sep 11.

29.

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.

Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI.

Sci Immunol. 2016 Aug;1(2). pii: aaf8943. doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.

30.

Dendritic cells in cancer: the role revisited.

Veglia F, Gabrilovich DI.

Curr Opin Immunol. 2017 Apr;45:43-51. doi: 10.1016/j.coi.2017.01.002. Epub 2017 Feb 10. Review.

31.

Myeloid-Derived Suppressor Cells.

Gabrilovich DI.

Cancer Immunol Res. 2017 Jan;5(1):3-8. doi: 10.1158/2326-6066.CIR-16-0297. Review.

32.

A neuronal network of mitochondrial dynamics regulates metastasis.

Caino MC, Seo JH, Aguinaldo A, Wait E, Bryant KG, Kossenkov AV, Hayden JE, Vaira V, Morotti A, Ferrero S, Bosari S, Gabrilovich DI, Languino LR, Cohen AR, Altieri DC.

Nat Commun. 2016 Dec 19;7:13730. doi: 10.1038/ncomms13730.

33.

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.

Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, Kumar P, Gabrilovich DI.

Clin Cancer Res. 2017 Jun 15;23(12):2942-2950. doi: 10.1158/1078-0432.CCR-16-1784. Epub 2016 Dec 13.

34.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

35.

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.

Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G, Penman E, Denstman F, Xu X, Altieri DC, Du H, Yan C, Gabrilovich DI.

Immunity. 2016 Feb 16;44(2):303-15. doi: 10.1016/j.immuni.2016.01.014.

36.

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Kumar V, Patel S, Tcyganov E, Gabrilovich DI.

Trends Immunol. 2016 Mar;37(3):208-220. doi: 10.1016/j.it.2016.01.004. Epub 2016 Feb 6. Review.

37.

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.

Ramachandran IR, Condamine T, Lin C, Herlihy SE, Garfall A, Vogl DT, Gabrilovich DI, Nefedova Y.

Cancer Lett. 2016 Feb 1;371(1):117-24. doi: 10.1016/j.canlet.2015.10.040. Epub 2015 Nov 27.

38.

Transcriptional regulation of myeloid-derived suppressor cells.

Condamine T, Mastio J, Gabrilovich DI.

J Leukoc Biol. 2015 Dec;98(6):913-22. doi: 10.1189/jlb.4RI0515-204R. Epub 2015 Sep 3. Review.

39.

GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.

Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, Bronte V, Murray PJ, Ting JP, Zeiser R, Blazar BR.

Blood. 2015 Sep 24;126(13):1621-8. doi: 10.1182/blood-2015-03-634691. Epub 2015 Aug 11.

40.

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Marvel D, Gabrilovich DI.

J Clin Invest. 2015 Sep;125(9):3356-64. doi: 10.1172/JCI80005. Epub 2015 Jul 13. Review.

41.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

42.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

43.

Editorial: The intricacy of choice: can bacteria decide what type of myeloid cells to stimulate?

Gabrilovich DI.

J Leukoc Biol. 2014 Nov;96(5):671-4. doi: 10.1189/jlb.4CE0514-271R. No abstract available.

44.

Regulation of tumor metastasis by myeloid-derived suppressor cells.

Condamine T, Ramachandran I, Youn JI, Gabrilovich DI.

Annu Rev Med. 2015;66:97-110. doi: 10.1146/annurev-med-051013-052304. Epub 2014 Oct 9. Review.

45.

Can the suppressive activity of myeloid-derived suppressor cells be "chop"ped?

Condamine T, Gabrilovich DI.

Immunity. 2014 Sep 18;41(3):341-342. doi: 10.1016/j.immuni.2014.08.016.

46.

Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment.

Kumar V, Gabrilovich DI.

Immunology. 2014 Dec;143(4):512-9. doi: 10.1111/imm.12380. Review.

47.

Molecular speciation and dynamics of oxidized triacylglycerols in lipid droplets: Mass spectrometry and coarse-grained simulations.

Mohammadyani D, Tyurin VA, O'Brien M, Sadovsky Y, Gabrilovich DI, Klein-Seetharaman J, Kagan VE.

Free Radic Biol Med. 2014 Nov;76:53-60. doi: 10.1016/j.freeradbiomed.2014.07.042. Epub 2014 Aug 10.

48.

COX-1-derived thromboxane A2 plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse.

Yang Q, Shi M, Shen Y, Cao Y, Zuo S, Zuo C, Zhang H, Gabrilovich DI, Yu Y, Zhou J.

Blood. 2014 Sep 4;124(10):1610-21. doi: 10.1182/blood-2014-03-559658. Epub 2014 Jul 16.

49.

Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice.

Kim S, Ramakrishnan R, Lavilla-Alonso S, Chinnaiyan P, Rao N, Fowler E, Heine J, Gabrilovich DI.

Cancer Immunol Immunother. 2014 Oct;63(10):1009-21. doi: 10.1007/s00262-014-1573-4. Epub 2014 Jun 19.

50.

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI.

J Clin Invest. 2014 Jun;124(6):2626-39. doi: 10.1172/JCI74056. Epub 2014 May 1.

Supplemental Content

Loading ...
Support Center